NCT05107375View on ClinicalTrials.gov

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

PHASE3CompletedINTERVENTIONAL

Enrollment

299

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions

Coronavirus Disease 2019

Interventions

BIOLOGICAL

Tetravalent influenza virus lysis vaccine

Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.

BIOLOGICAL

Recombinant new coronavirus vaccine (CHO cell) group

One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.

Trial Locations (1)

411228

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT05107375 - Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine | Biotech Hunter | Biotech Hunter